Andreas Argyrides
Stock Analyst at Oppenheimer
(4.43)
# 296
Out of 5,072 analysts
118
Total ratings
50%
Success rate
21.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SVRA Savara | Maintains: Outperform | $8 → $9 | $5.36 | +67.91% | 2 | Nov 14, 2025 | |
| KROS Keros Therapeutics | Reiterates: Outperform | $23 → $27 | $17.50 | +54.29% | 9 | Nov 12, 2025 | |
| DYN Dyne Therapeutics | Maintains: Perform | $13 → $11 | $21.17 | -48.04% | 4 | Nov 12, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Outperform | $77 → $115 | $87.36 | +31.64% | 2 | Oct 2, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $26 → $21 | $3.53 | +494.90% | 2 | Oct 2, 2025 | |
| BNTC Benitec Biopharma | Maintains: Outperform | $35 → $29 | $13.02 | +122.82% | 2 | Sep 16, 2025 | |
| KALA KALA BIO | Maintains: Outperform | $15 → $33 | $0.91 | +3,524.78% | 2 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Outperform | $510 → $575 | $488.43 | +17.72% | 1 | Sep 5, 2025 | |
| MNKD MannKind | Maintains: Outperform | $12 → $15 | $5.38 | +178.81% | 2 | Sep 5, 2025 | |
| ABEO Abeona Therapeutics | Maintains: Outperform | $19 → $20 | $5.15 | +288.35% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $61 | $35.56 | +71.54% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 → $7 | $6.22 | +12.54% | 5 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $3 | $1.19 | +152.10% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $13 | $31.72 | -59.02% | 7 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $4 | $1.62 | +146.91% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $155 → $90 | $5.52 | +1,530.43% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $9 | $2.34 | +284.62% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $210.01 | -13.81% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $104 | $13.80 | +653.62% | 14 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $0.56 | +13,261.84% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $3.34 | +169.46% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $9.57 | +98.54% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $18.91 | +53.36% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $13.26 | +58.37% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $20.95 | +969.21% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $23.81 | +139.40% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.70 | +898.57% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.46 | +2,054.71% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $55.52 | +26.08% | 6 | Aug 1, 2023 |
Savara
Nov 14, 2025
Maintains: Outperform
Price Target: $8 → $9
Current: $5.36
Upside: +67.91%
Keros Therapeutics
Nov 12, 2025
Reiterates: Outperform
Price Target: $23 → $27
Current: $17.50
Upside: +54.29%
Dyne Therapeutics
Nov 12, 2025
Maintains: Perform
Price Target: $13 → $11
Current: $21.17
Upside: -48.04%
Monopar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $77 → $115
Current: $87.36
Upside: +31.64%
Larimar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $26 → $21
Current: $3.53
Upside: +494.90%
Benitec Biopharma
Sep 16, 2025
Maintains: Outperform
Price Target: $35 → $29
Current: $13.02
Upside: +122.82%
KALA BIO
Sep 11, 2025
Maintains: Outperform
Price Target: $15 → $33
Current: $0.91
Upside: +3,524.78%
United Therapeutics
Sep 5, 2025
Maintains: Outperform
Price Target: $510 → $575
Current: $488.43
Upside: +17.72%
MannKind
Sep 5, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $5.38
Upside: +178.81%
Abeona Therapeutics
Aug 15, 2025
Maintains: Outperform
Price Target: $19 → $20
Current: $5.15
Upside: +288.35%
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $35.56
Upside: +71.54%
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $6.22
Upside: +12.54%
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $1.19
Upside: +152.10%
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $31.72
Upside: -59.02%
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $1.62
Upside: +146.91%
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $5.52
Upside: +1,530.43%
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $2.34
Upside: +284.62%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $210.01
Upside: -13.81%
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $13.80
Upside: +653.62%
Jun 25, 2024
Initiates: Outperform
Price Target: $75
Current: $0.56
Upside: +13,261.84%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $3.34
Upside: +169.46%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $9.57
Upside: +98.54%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $18.91
Upside: +53.36%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $13.26
Upside: +58.37%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $20.95
Upside: +969.21%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $23.81
Upside: +139.40%
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.70
Upside: +898.57%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.46
Upside: +2,054.71%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $55.52
Upside: +26.08%